Core Viewpoint - Medline, a leading manufacturer and distributor of medical supplies, has filed for an initial public offering (IPO) with a potential fundraising target of up to $5 billion, which would be the largest IPO since Rivian's in 2021 [1][2] Company Overview - Medline is a major distributor and manufacturer of surgical products, offering approximately 335,000 products across two main segments: "Medline Private Brand" and "Supply Chain Solutions" [1] - The "Medline Private Brand" segment includes products manufactured in-house and private label products, while the "Supply Chain Solutions" segment focuses on distributing third-party medical supplies and providing logistics and procurement services to healthcare institutions [1] - About one-third of Medline's private brand products are manufactured in 33 global production facilities, with the remainder sourced from over 500 suppliers [1] Distribution and Logistics - Medline operates a distribution network comprising 69 logistics facilities and over 2,000 trucks, enabling service to approximately 95% of U.S. customers within one day [1] - The company collaborates with over 1,300 healthcare institutions through long-term supply agreements and is expanding into laboratory, animal health, and international markets [1] Financial Performance - For the 12 months ending June 28, 2025, Medline reported revenues of $32.9 billion [2] - The company plans to list on NASDAQ under the ticker symbol MDLN and has submitted a confidential filing on December 19, 2024 [2] - Major banks involved in the IPO include Goldman Sachs, Morgan Stanley, Bank of America Securities, and JPMorgan [2]